ADAMs family and relatives in cardiovascular physiology and pathology

Journal of Molecular and Cellular Cardiology

Volumn 93, Issue , 2016, Pages 186-199

  Zhang, Pu ^a   Shen, Mengcheng ^a   Fernandez Patron, Carlos ^a   Kassiri, Zamaneh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

ADAM TS; ADAMs; Heart disease; Remodeling

Indexed keywords

ADAM PROTEIN; ADAM10 ENDOPEPTIDASE; ADAM11 PROTEIN; ADAM15 PROTEIN; ADAM17 PROTEIN; ADAM19 PROTEIN; ADAM8 PROTEIN; ADAM9 PROTEIN; ADAMTS1 PROTEIN; METALLOPROTEINASE; UNCLASSIFIED DRUG; PROTEIN BINDING;

CARDIOVASCULAR DISEASE; DISEASE ACTIVITY; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SUBSTRATE; HUMAN; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; PROTEIN STRUCTURE; REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; CARDIOVASCULAR FUNCTION; CHEMISTRY; DISEASE MODEL; ENZYME SPECIFICITY; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MULTIGENE FAMILY; MUTATION; ORGANOGENESIS; PROTEIN DOMAIN;

ADAM PROTEINS; ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; MULTIGENE FAMILY; MUTATION; ORGANOGENESIS; POLYMORPHISM, GENETIC; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; SUBSTRATE SPECIFICITY;

EID: 84963818006     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.10.031     Document Type: Review

References (186)

1. Fan D., Creemers E.E., Kassiri Z. Matrix as an interstitial transport system. Circ. Res. 2014 Feb 28, 114(5):889-902.
2. Takawale A., Sakamuri S.S., Kassiri Z. Extracellular matrix communication and turnover in cardiac physiology and pathology. Comprehensive Physiology 2015 Apr, 5(2):687-719.
3. Seals D.F., Courtneidge S.A. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 2003 Jan 1, 17(1):7-30.
4. Fedak P.W., Moravec C.S., McCarthy P.M., Altamentova S.M., Wong A.P., Skrtic M., et al. Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy. Circulation 2006 Jan 17, 113(2):238-245.
5. Arndt M., Lendeckel U., Rocken C., Nepple K., Wolke C., Spiess A., et al. Altered expression of ADAMs (a disintegrin and metalloproteinase) in fibrillating human atria. Circulation 2002 Feb 12, 105(6):720-725.
6. Wu W., Zhou Y., Li Y., Li J., Ke Y., Wang Y., et al. Association between plasma ADAMTS-7 levels and ventricular remodeling in patients with acute myocardial infarction. Eur J Med Res. 2015, 20:27.
7. Hassan S., Westwood J.P., Ellis D., Laing C., Mc Guckin S., Benjamin S., et al. The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry. Br. J. Haematol. 2015 Sep, 11.
8. Blobel C.P. Metalloprotease-disintegrins: links to cell adhesion and cleavage of TNF alpha and notch. Cell 1997 Aug 22, 90(4):589-592.
9. Blobel C.P., White J.M. Structure, function and evolutionary relationship of proteins containing a disintegrin domain. Curr. Opin. Cell Biol. 1992 Oct, 4(5):760-765.
10. Blobel C.P. ADAMs: key components in EGFR signalling and development. Nat. Rev. Mol. Cell Biol. 2005 Jan, 6(1):32-43.
11. Edwards D.R., Handsley M.M., Pennington C.J. The ADAM metalloproteinases. Mol. Asp. Med. 2008 Oct, 29(5):258-289.
12. Puente X.S., Lopez-Otin C. A genomic analysis of rat proteases and protease inhibitors. Genome Res. 2004 Apr, 14(4):609-622.
13. Van Wart H.E., Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. U. S. A. 1990 Jul, 87(14):5578-5582.
14. White J.M. ADAMs: modulators of cell-cell and cell-matrix interactions. Curr. Opin. Cell Biol. 2003 Oct, 15(5):598-606.
15. Takeda S., Igarashi T., Mori H., Araki S. Crystal structures of VAP1 reveal ADAMs' MDC domain architecture and its unique C-shaped scaffold. EMBO J 2006 Jun 7, 25(11):2388-2396.
16. Igarashi T., Araki S., Mori H., Takeda S. Crystal structures of catrocollastatin/VAP2B reveal a dynamic, modular architecture of ADAM/adamalysin/reprolysin family proteins. FEBS Lett. 2007 May 29, 581(13):2416-2422.
17. Iba K., Albrechtsen R., Gilpin B., Frohlich C., Loechel F., Zolkiewska A., et al. The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to beta1 integrin-dependent cell spreading. J. Cell Biol. 2000 May 29, 149(5):1143-1156.
18. Smith K.M., Gaultier A., Cousin H., Alfandari D., White J.M., DeSimone D.W. The cysteine-rich domain regulates ADAM protease function in vivo. J. Cell Biol. 2002 Dec 9, 159(5):893-902.
19. Wewer U.M., Morgelin M., Holck P., Jacobsen J., Lydolph M.C., Johnsen A.H., et al. ADAM12 is a four-leafed clover: the excised prodomain remains bound to the mature enzyme. J Biol Chem 2006 Apr 7, 281(14):9418-9422.
20. Mazzocca A., Coppari R., De Franco R., Cho J.Y., Libermann T.A., Pinzani M., et al. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res. 2005 Jun 1, 65(11):4728-4738.
21. Katagiri T., Harada Y., Emi M., Nakamura Y. Human metalloprotease/disintegrin-like (MDC) gene: exon-intron organization and alternative splicing. Cytogenet. Cell Genet. 1995, 68(1-2):39-44.
22. Fourie A.M., Coles F., Moreno V., Karlsson L. Catalytic activity of ADAM8, ADAM15, and MDC-L (ADAM28) on synthetic peptide substrates and in ectodomain cleavage of CD23. J Biol Chem 2003 Aug 15, 278(33):30469-30477.
23. Kleino I., Ortiz R.M., Huovila A.P. ADAM15 gene structure and differential alternative exon use in human tissues. BMC Mol. Biol. 2007, 8:90.
24. Sagane K., Hayakawa K., Kai J., Hirohashi T., Takahashi E., Miyamoto N., et al. Ataxia and peripheral nerve hypomyelination in ADAM22-deficient mice. BMC Neurosci. 2005, 6:33.
25. Kurisaki T., Wakatsuki S., Sehara-Fujisawa A. Meltrin beta mini, a new ADAM19 isoform lacking metalloprotease and disintegrin domains, induces morphological changes in neuronal cells. FEBS Lett. 2002 Dec 18, 532(3):419-422.
26. Lum L., Reid M.S., Blobel C.P. Intracellular maturation of the mouse metalloprotease disintegrin MDC15. J Biol Chem 1998 Oct 2, 273(40):26236-26247.
27. Schlomann U., Wildeboer D., Webster A., Antropova O., Zeuschner D., Knight C.G., et al. The metalloprotease disintegrin ADAM8. Processing by autocatalysis is required for proteolytic activity and cell adhesion. J Biol Chem 2002 Dec 13, 277(50):48210-48219.
28. Howard L., Maciewicz R.A., Blobel C.P. Cloning and characterization of ADAM28: evidence for autocatalytic pro-domain removal and for cell surface localization of mature ADAM28. Biochem. J. 2000 May 15, 348(Pt 1):21-27.
29. Anders A., Gilbert S., Garten W., Postina R., Fahrenholz F. Regulation of the alpha-secretase ADAM10 by its prodomain and proprotein convertases. FASEB J. 2001 Aug, 15(10):1837-1839.
30. Sundberg C., Thodeti C.K., Kveiborg M., Larsson C., Parker P., Albrechtsen R., et al. Regulation of ADAM12 cell-surface expression by protein kinase C epsilon. J Biol Chem 2004 Dec 3, 279(49):51601-51611.
31. Cao Y., Kang Q., Zhao Z., Zolkiewska A. Intracellular processing of metalloprotease disintegrin ADAM12. J Biol Chem 2002 Jul 19, 277(29):26403-26411.
32. Koller G., Schlomann U., Golfi P., Ferdous T., Naus S., Bartsch J.W. ADAM8/MS2/CD156, an emerging drug target in the treatment of inflammatory and invasive pathologies. Curr. Pharm. Des. 2009, 15(20):2272-2281.
33. Reddy P., Slack J.L., Davis R., Cerretti D.P., Kozlosky C.J., Blanton R.A., et al. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem 2000 May 12, 275(19):14608-14614.
34. Wakatsuki S., Kurisaki T., Sehara-Fujisawa A. Lipid rafts identified as locations of ectodomain shedding mediated by Meltrin beta/ADAM19. J. Neurochem. 2004 Apr, 89(1):119-123.
35. Fan H., Turck C.W., Derynck R. Characterization of growth factor-induced serine phosphorylation of tumor necrosis factor-alpha converting enzyme and of an alternatively translated polypeptide. J Biol Chem 2003 May 16, 278(20):18617-18627.
36. Doedens J.R., Mahimkar R.M., Black R.A. TACE/ADAM-17 enzymatic activity is increased in response to cellular stimulation. Biochem. Biophys. Res. Commun. 2003 Aug 22, 308(2):331-338.
37. Fischer O.M., Hart S., Gschwind A., Ullrich A. EGFR signal transactivation in cancer cells. Biochem. Soc. Trans. 2003 Dec, 31(Pt 6):1203-1208.
38. Zhang Q., Thomas S.M., Lui V.W., Xi S., Siegfried J.M., Fan H., et al. Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc. Natl. Acad. Sci. U. S. A. 2006 May 2, 103(18):6901-6906.
39. Diaz-Rodriguez E., Montero J.C., Esparis-Ogando A., Yuste L., Pandiella A. Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. Mol. Biol. Cell 2002 Jun, 13(6):2031-2044.
40. Xu P., Derynck R. Direct activation of TACE-mediated ectodomain shedding by p38 MAP kinase regulates EGF receptor-dependent cell proliferation. Mol. Cell 2010 Feb 26, 37(4):551-566.
41. Patel V.B., Clarke N., Wang Z., Fan D., Parajuli N., Basu R., et al. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. J. Mol. Cell. Cardiol. 2014 Jan, 66:167-176.
42. Soond S.M., Everson B., Riches D.W., Murphy G. ERK-mediated phosphorylation of Thr735 in TNFalpha-converting enzyme and its potential role in TACE protein trafficking. J. Cell Sci. 2005 Jun 1, 118(Pt 11):2371-2380.
43. Niu A., Wang B., Li Y.P. TNFalpha shedding in mechanically stressed cardiomyocytes is mediated by Src activation of TACE. J. Cell. Biochem. 2015 Apr, 116(4):559-565.
44. Arribas J., Bech-Serra J.J., Santiago-Josefat B. ADAMs, cell migration and cancer. Cancer Metastasis Rev. 2006 Mar, 25(1):57-68.
45. Amour A., Knight C.G., Webster A., Slocombe P.M., Stephens P.E., Knauper V., et al. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett. 2000 May 19, 473(3):275-279.
46. Amour A., Knight C.G., English W.R., Webster A., Slocombe P.M., Knauper V., et al. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett. 2002 Jul 31, 524(1-3):154-158.
47. Chesneau V., Becherer J.D., Zheng Y., Erdjument-Bromage H., Tempst P., Blobel C.P. Catalytic properties of ADAM19. J Biol Chem 2003 Jun 20, 278(25):22331-22340.
48. Amour A., Slocombe P.M., Webster A., Butler M., Knight C.G., Smith B.J., et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 1998 Sep 11, 435(1):39-44.
49. Jacobsen J., Visse R., Sorensen H.P., Enghild J.J., Brew K., Wewer U.M., et al. Catalytic properties of ADAM12 and its domain deletion mutants. Biochemistry 2008 Jan 15, 47(2):537-547.
50. Zou J., Zhu F., Liu J., Wang W., Zhang R., Garlisi C.G., et al. Catalytic activity of human ADAM33. J Biol Chem 2004 Mar 12, 279(11):9818-9830.
51. Rapti M., Atkinson S.J., Lee M.H., Trim A., Moss M., Murphy G. The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition. Biochem. J. 2008 Apr 15, 411(2):433-439.
52. Lee M.H., Dodds P., Verma V., Maskos K., Knauper V., Murphy G. Tailoring tissue inhibitor of metalloproteinases-3 to overcome the weakening effects of the cysteine-rich domains of tumour necrosis factor-alpha converting enzyme. Biochem. J. 2003 Apr 15, 371(Pt 2):369-376.
53. Wei S., Kashiwagi M., Kota S., Xie Z., Nagase H., Brew K. Reactive site mutations in tissue inhibitor of metalloproteinase-3 disrupt inhibition of matrix metalloproteinases but not tumor necrosis factor-alpha-converting enzyme. J Biol Chem 2005 Sep 23, 280(38):32877-32882.
54. Xu P., Liu J., Sakaki-Yumoto M., Derynck R. TACE activation by MAPK-mediated regulation of cell surface dimerization and TIMP3 association. Sci Signal. 2012 May 1, 5(222).
55. Muraguchi T., Takegami Y., Ohtsuka T., Kitajima S., Chandana E.P., Omura A., et al. RECK modulates notch signaling during cortical neurogenesis by regulating ADAM10 activity. Nat. Neurosci. 2007 Jul, 10(7):838-845.
56. Moss M.L., Bomar M., Liu Q., Sage H., Dempsey P., Lenhart P.M., et al. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events. J Biol Chem 2007 Dec 7, 282(49):35712-35721.
57. Gonzales P.E., Solomon A., Miller A.B., Leesnitzer M.A., Sagi I., Milla M.E. Inhibition of the tumor necrosis factor-alpha-converting enzyme by its pro domain. J Biol Chem 2004 Jul 23, 279(30):31638-31645.
58. Srinivasan S., Romagnoli M., Bohm A., Sonenshein G.E. N-glycosylation regulates ADAM8 processing and activation. J Biol Chem 2014 Nov 28, 289(48):33676-33688.
59. Fry J.L., Toker A. Secreted and membrane-bound isoforms of protease ADAM9 have opposing effects on breast cancer cell migration. Cancer Res. 2010 Oct 15, 70(20):8187-8198.
60. Kodama T., Ikeda E., Okada A., Ohtsuka T., Shimoda M., Shiomi T., et al. ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. Am J Pathol 2004 Nov, 165(5):1743-1753.
61. Howard L., Nelson K.K., Maciewicz R.A., Blobel C.P. Interaction of the metalloprotease disintegrins MDC9 and MDC15 with two SH3 domain-containing proteins, endophilin I and SH3PX1. J Biol Chem 1999 Oct 29, 274(44):31693-31699.
62. Chavaroche A., Cudic M., Giulianotti M., Houghten R.A., Fields G.B., Minond D. Glycosylation of a disintegrin and metalloprotease 17 affects its activity and inhibition. Anal. Biochem. 2014 Mar 15, 449:68-75.
63. Minond D., Cudic M., Bionda N., Giulianotti M., Maida L., Houghten R.A., et al. Discovery of novel inhibitors of a disintegrin and metalloprotease 17 (ADAM17) using glycosylated and non-glycosylated substrates. J Biol Chem 2012 Oct 19, 287(43):36473-36487.
64. Ray B.K., Dhar S., Henry C., Rich A., Ray A. Epigenetic regulation by Z-DNA silencer function controls cancer-associated ADAM-12 expression in breast cancer: cross-talk between MeCP2 and NF1 transcription factor family. Cancer Res. 2013 Jan 15, 73(2):736-744.
65. Nakao K., Miyaaki H., Ichikawa T. Antitumor function of microRNA-122 against hepatocellular carcinoma. J. Gastroenterol. 2014 Apr, 49(4):589-593.
66. Ehrnsperger A., Rehli M., Thu-Hang P., Kreutz M. Epigenetic regulation of the dendritic cell-marker gene ADAM19. Biochem. Biophys. Res. Commun. 2005 Jul 1, 332(2):456-464.
67. Chan M.W., Huang Y.W., Hartman-Frey C., Kuo C.T., Deatherage D., Qin H., et al. Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. Neoplasia 2008 Sep, 10(9):908-919.
68. Yang Y., Haitchi H.M., Cakebread J., Sammut D., Harvey A., Powell R.M., et al. Epigenetic mechanisms silence a disintegrin and metalloprotease 33 expression in bronchial epithelial cells. The Journal of Allergy and Clinical Immunology 2008 Jun, 121(6):1393-1399.
69. Albrechtsen R., Kveiborg M., Stautz D., Vikesa J., Noer J.B., Kotzsh A., et al. ADAM12 redistributes and activates MMP-14, resulting in gelatin degradation, reduced apoptosis and increased tumor growth. J. Cell Sci. 2013 Oct 15, 126(Pt 20):4707-4720.
70. Mochizuki S., Shimoda M., Shiomi T., Fujii Y., Okada Y. ADAM28 is activated by MMP-7 (matrilysin-1) and cleaves insulin-like growth factor binding protein-3. Biochem. Biophys. Res. Commun. 2004 Feb 27, 315(1):79-84.
71. Chan K.M., Wong H.L., Jin G., Liu B., Cao R., Cao Y., et al. MT1-MMP inactivates ADAM9 to regulate FGFR2 signaling and calvarial osteogenesis. Dev. Cell 2012 Jun 12, 22(6):1176-1190.
72. Wang X., Chow F.L., Oka T., Hao L., Lopez-Campistrous A., Kelly S., et al. Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy. Circulation 2009 May 12, 119(18):2480-2489.
73. Xiao L.J., Lin P., Lin F., Liu X., Qin W., Zou H.F., et al. ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion. Int. J. Oncol. 2012 May, 40(5):1714-1724.
74. Li Y.Q., Yan J.P., Xu W.L., Wang H., Xia Y.J., Wang H.J., et al. ADAM17 mediates MMP9 expression in lung epithelial cells. PLoS One 2013, 8(1).
75. Odenbach J., Wang X., Cooper S., Chow F.L., Oka T., Lopaschuk G., et al. MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension 2011 Jan, 57(1):123-130.
76. Hartmann D., de Strooper B., Serneels L., Craessaerts K., Herreman A., Annaert W., et al. The disintegrin/metalloprotease ADAM 10 is essential for notch signalling but not for alpha-secretase activity in fibroblasts. Hum. Mol. Genet. 2002 Oct 1, 11(21):2615-2624.
77. Zhang C., Tian L., Chi C., Wu X., Yang X., Han M., et al. Adam10 is essential for early embryonic cardiovascular development. Developmental Dynamics: An Official Publication of the American Association of Anatomists 2010 Oct, 239(10):2594-2602.
78. Najy A.J., Day K.C., Day M.L. The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J Biol Chem 2008 Jun 27, 283(26):18393-18401.
79. Sun C., Wu M.H., Lee E.S., Yuan S.Y. A disintegrin and metalloproteinase 15 contributes to atherosclerosis by mediating endothelial barrier dysfunction via Src family kinase activity. Arterioscler. Thromb. Vasc. Biol. 2012 Oct, 32(10):2444-2451.
80. Sun C., Wu M.H., Guo M., Day M.L., Lee E.S., Yuan S.Y. ADAM15 regulates endothelial permeability and neutrophil migration via Src/ERK1/2 signalling. Cardiovasc. Res. 2010 Jul 15, 87(2):348-355.
81. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997 Feb 20, 385(6618):729-733.
82. Moss M.L., Jin S.L., Milla M.E., Bickett D.M., Burkhart W., Carter H.L., et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997 Feb 20, 385(6618):733-736.
83. Sato T., Suzuki H., Shibata M., Kusuyama T., Omori Y., Soda T., et al. Tumor-necrosis-factor-alpha-gene-deficient mice have improved cardiac function through reduction of intercellular adhesion molecule-1 in myocardial infarction. Circ. J. 2006 Dec, 70(12):1635-1642.
84. Sun M., Chen M., Dawood F., Zurawska U., Li J.Y., Parker T., et al. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 2007 Mar 20, 115(11):1398-1407.
85. Coletta A.P., Clark A.L., Banarjee P., Cleland J.G. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur. J. Heart Fail. 2002 Aug, 4(4):559-561.
86. Anker S.D., Coats A.J. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol. 2002 Dec, 86(2-3):123-130.
87. Weskamp G., Schlondorff J., Lum L., Becherer J.D., Kim T.W., Saftig P., et al. Evidence for a critical role of the tumor necrosis factor alpha convertase (TACE) in ectodomain shedding of the p75 neurotrophin receptor (p75NTR). J Biol Chem 2004 Feb 6, 279(6):4241-4249.
88. Lunn C.A., Fan X., Dalie B., Miller K., Zavodny P.J., Narula S.K., et al. Purification of ADAM 10 from bovine spleen as a TNFalpha convertase. FEBS Lett. 1997 Jan 6, 400(3):333-335.
89. Rosendahl M.S., Ko S.C., Long D.L., Brewer M.T., Rosenzweig B., Hedl E., et al. Identification and characterization of a pro-tumor necrosis factor-alpha-processing enzyme from the ADAM family of zinc metalloproteases. J Biol Chem 1997 Sep 26, 272(39):24588-24593.
90. English W.R., Puente X.S., Freije J.M., Knauper V., Amour A., Merryweather A., et al. Membrane type 4 matrix metalloproteinase (MMP17) has tumor necrosis factor-alpha convertase activity but does not activate pro-MMP2. J Biol Chem 2000 May 12, 275(19):14046-14055.
91. Peschon J.J., Slack J.L., Reddy P., Stocking K.L., Sunnarborg S.W., Lee D.C., et al. An essential role for ectodomain shedding in mammalian development. Science 1998 Nov 13, 282(5392):1281-1284.
92. Higashiyama S., Nanba D. ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk. Biochim. Biophys. Acta 2005 Aug 1, 1751(1):110-117.
93. Sahul Z.H., Mukherjee R., Song J., McAteer J., Stroud R.E., Dione D.P., et al. Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction. Circulation Cardiovascular Imaging 2011 Jul, 4(4):381-391.
94. Lee D.C., Sunnarborg S.W., Hinkle C.L., Myers T.J., Stevenson M.Y., Russell W.E., et al. TACE/ADAM17 processing of EGFR ligands indicates a role as a physiological convertase. Ann. N. Y. Acad. Sci. 2003 May, 995:22-38.
95. Jackson L.F., Qiu T.H., Sunnarborg S.W., Chang A., Zhang C., Patterson C., et al. Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. EMBO J 2003 Jun 2, 22(11):2704-2716.
96. Shi W., Chen H., Sun J., Buckley S., Zhao J., Anderson K.D., et al. TACE is required for fetal murine cardiac development and modeling. Dev. Biol. 2003 Sep 15, 261(2):371-380.
97. Sahin U., Weskamp G., Kelly K., Zhou H.M., Higashiyama S., Peschon J., et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J. Cell Biol. 2004 Mar 1, 164(5):769-779.
98. Asakura M., Kitakaze M., Takashima S., Liao Y., Ishikura F., Yoshinaka T., et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat. Med. 2002 Jan, 8(1):35-40.
99. Kurisaki T., Masuda A., Sudo K., Sakagami J., Higashiyama S., Matsuda Y., et al. Phenotypic analysis of Meltrin alpha (ADAM12)-deficient mice: involvement of Meltrin alpha in adipogenesis and myogenesis. Mol. Cell. Biol. 2003 Jan, 23(1):55-61.
100. Dyczynska E., Sun D., Yi H., Sehara-Fujisawa A., Blobel C.P., Zolkiewska A. Proteolytic processing of delta-like 1 by ADAM proteases. J. Biol. Chem. 2007 Jan 5, 282(1):436-444.
101. Wild-Bode C., Fellerer K., Kugler J., Haass C., Capell A. A basolateral sorting signal directs ADAM10 to adherens junctions and is required for its function in cell migration. J. Biol. Chem. 2006 Aug 18, 281(33):23824-23829.
102. Kelwick R., Desanlis I., Wheeler G.N., Edwards D.R. The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family. Genome Biol. 2015, 16:113.
103. Stanton H., Melrose J., Little C.B., Fosang A.J. Proteoglycan degradation by the ADAMTS family of proteinases. Biochim. Biophys. Acta 2011 Dec, 1812(12):1616-1629.
104. Colige A., Vandenberghe I., Thiry M., Lambert C.A., Van Beeumen J., Li S.W., et al. Cloning and characterization of ADAMTS-14, a novel ADAMTS displaying high homology with ADAMTS-2 and ADAMTS-3. J. Biol. Chem. 2002 Feb 22, 277(8):5756-5766.
105. Fujikawa K., Suzuki H., McMullen B., Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001 Sep 15, 98(6):1662-1666.
106. Liu C.J., Kong W., Ilalov K., Yu S., Xu K., Prazak L., et al. ADAMTS-7: a metalloproteinase that directly binds to and degrades cartilage oligomeric matrix protein. FASEB J. 2006 May, 20(7):988-990.
107. Liu C.J., Kong W., Xu K., Luan Y., Ilalov K., Sehgal B., et al. ADAMTS-12 associates with and degrades cartilage oligomeric matrix protein. J. Biol. Chem. 2006 Jun 9, 281(23):15800-15808.
108. Majerus E.M., Zheng X., Tuley E.A., Sadler J.E. Cleavage of the ADAMTS13 propeptide is not required for protease activity. J. Biol. Chem. 2003 Nov 21, 278(47):46643-46648.
109. Rodriguez-Manzaneque J.C., Milchanowski A.B., Dufour E.K., Leduc R., Iruela-Arispe M.L. Characterization of METH-1/ADAMTS1 processing reveals two distinct active forms. J. Biol. Chem. 2000 Oct 27, 275(43):33471-33479.
110. Wang P., Tortorella M., England K., Malfait A.M., Thomas G., Arner E.C., et al. Proprotein convertase furin interacts with and cleaves pro-ADAMTS4 (aggrecanase-1) in the trans-Golgi network. J. Biol. Chem. 2004 Apr 9, 279(15):15434-15440.
111. Longpre J.M., McCulloch D.R., Koo B.H., Alexander J.P., Apte S.S., Leduc R. Characterization of proADAMTS5 processing by proprotein convertases. Int. J. Biochem. Cell Biol. 2009 May, 41(5):1116-1126.
112. Koo B.H., Longpre J.M., Somerville R.P., Alexander J.P., Leduc R., Apte S.S. Regulation of ADAMTS9 secretion and enzymatic activity by its propeptide. J. Biol. Chem. 2007 Jun 1, 282(22):16146-16154.
113. Koo B.H., Apte S.S. Cell-surface processing of the metalloprotease pro-ADAMTS9 is influenced by the chaperone GRP94/gp96. J. Biol. Chem. 2010 Jan 1, 285(1):197-205.
114. Gao G., Plaas A., Thompson V.P., Jin S., Zuo F., Sandy J.D. ADAMTS4 (aggrecanase-1) activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparan sulfate on syndecan-1. J. Biol. Chem. 2004 Mar 12, 279(11):10042-10051.
115. Lim N.H., Kashiwagi M., Visse R., Jones J., Enghild J.J., Brew K., et al. Reactive-site mutants of N-TIMP-3 that selectively inhibit ADAMTS-4 and ADAMTS-5: biological and structural implications. Biochem. J. 2010 Oct 1, 431(1):113-122.
116. Wang W.M., Ge G., Lim N.H., Nagase H., Greenspan D.S. TIMP-3 inhibits the procollagen N-proteinase ADAMTS-2. Biochem. J. 2006 Sep 15, 398(3):515-519.
117. Hashimoto G., Aoki T., Nakamura H., Tanzawa K., Okada Y. Inhibition of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4). FEBS Lett. 2001 Apr 13, 494(3):192-195.
118. Rodriguez-Manzaneque J.C., Westling J., Thai S.N., Luque A., Knauper V., Murphy G., et al. ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. Biochem. Biophys. Res. Commun. 2002 Apr 26, 293(1):501-508.
119. Tortorella M.D., Arner E.C., Hills R., Easton A., Korte-Sarfaty J., Fok K., et al. Alpha2-macroglobulin is a novel substrate for ADAMTS-4 and ADAMTS-5 and represents an endogenous inhibitor of these enzymes. J. Biol. Chem. 2004 Apr 23, 279(17):17554-17561.
120. Lind G.E., Kleivi K., Meling G.I., Teixeira M.R., Thiis-Evensen E., Rognum T.O., et al. ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis. Cell. Oncol. 2006, 28(5-6):259-272.
121. Moncada-Pazos A., Obaya A.J., Fraga M.F., Viloria C.G., Capella G., Gausachs M., et al. The ADAMTS12 metalloprotease gene is epigenetically silenced in tumor cells and transcriptionally activated in the stroma during progression of colon cancer. J. Cell Sci. 2009 Aug 15, 122(Pt 16):2906-2913.
122. Lung H.L., Lo P.H., Xie D., Apte S.S., Cheung A.K., Cheng Y., et al. Characterization of a novel epigenetically-silenced, growth-suppressive gene, ADAMTS9, and its association with lymph node metastases in nasopharyngeal carcinoma. Int. J. Cancer 2008 Jul 15, 123(2):401-408.
123. Jin H., Wang X., Ying J., Wong A.H., Li H., Lee K.Y., et al. Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas. Oncogene 2007 Nov 22, 26(53):7490-7498.
124. Cho C. Testicular and epididymal ADAMs: expression and function during fertilization. Nat. Rev. Urol. 2012 Oct, 9(10):550-560.
125. King N.E., Zimmermann N., Pope S.M., Fulkerson P.C., Nikolaidis N.M., Mishra A., et al. Expression and regulation of a disintegrin and metalloproteinase (ADAM) 8 in experimental asthma. Am. J. Respir. Cell Mol. Biol. 2004 Sep, 31(3):257-265.
126. Kelly K., Hutchinson G., Nebenius-Oosthuizen D., Smith A.J., Bartsch J.W., Horiuchi K., et al. Metalloprotease-disintegrin ADAM8: expression analysis and targeted deletion in mice. Developmental Dynamics: An Official Publication of the American Association of Anatomists 2005 Jan, 232(1):221-231.
127. Vuohelainen V., Raitoharju E., Levula M., Lehtimaki T., Pelto-Huikko M., Honkanen T., et al. Myocardial infarction induces early increased remote ADAM8 expression of rat hearts after cardiac arrest. Scand. J. Clin. Lab. Invest. 2011 Nov, 71(7):553-562.
128. Weskamp G., Cai H., Brodie T.A., Higashyama S., Manova K., Ludwig T., et al. Mice lacking the metalloprotease-disintegrin MDC9 (ADAM9) have no evident major abnormalities during development or adult life. Mol. Cell. Biol. 2002 Mar, 22(5):1537-1544.
129. Takahashi E., Sagane K., Oki T., Yamazaki K., Nagasu T., Kuromitsu J. Deficits in spatial learning and motor coordination in ADAM11-deficient mice. BMC Neurosci. 2006, 7:19.
130. Rybnikova E., Karkkainen I., Pelto-Huikko M., Huovila A.P. Developmental regulation and neuronal expression of the cellular disintegrin ADAM11 gene in mouse nervous system. Neuroscience 2002, 112(4):921-934.
131. Takahashi E., Sagane K., Nagasu T., Kuromitsu J. Altered nociceptive response in ADAM11-deficient mice. Brain Res. 2006 Jun 30, 1097(1):39-42.
132. Yagami-Hiromasa T., Sato T., Kurisaki T., Kamijo K., Nabeshima Y., Fujisawa-Sehara A. A metalloprotease-disintegrin participating in myoblast fusion. Nature 1995 Oct 19, 377(6550):652-656.
133. Horiuchi K., Zhou H.M., Kelly K., Manova K., Blobel C.P. Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins beta1 and beta2. Dev. Biol. 2005 Jul 15, 283(2):459-471.
134. Maretzky T., Yang G., Ouerfelli O., Overall C.M., Worpenberg S., Hassiepen U., et al. Characterization of the catalytic activity of the membrane-anchored metalloproteinase ADAM15 in cell-based assays. Biochem. J. 2009 May 15, 420(1):105-113.
135. Lucas N., Day M.L. The role of the disintegrin metalloproteinase ADAM15 in prostate cancer progression. J. Cell. Biochem. 2009 Apr 15, 106(6):967-974.
136. Al-Fakhri N., Wilhelm J., Hahn M., Heidt M., Hehrlein F.W., Endisch A.M., et al. Increased expression of disintegrin-metalloproteinases ADAM-15 and ADAM-9 following upregulation of integrins alpha5beta1 and alphavbeta3 in atherosclerosis. J. Cell. Biochem. 2003 Jul 1, 89(4):808-823.
137. Bohm B.B., Aigner T., Blobel C.P., Kalden J.R., Burkhardt H. Highly enhanced expression of the disintegrin metalloproteinase MDC15 (metargidin) in rheumatoid synovial tissue. Arthritis Rheum. 2001 Sep, 44(9):2046-2054.
138. Horiuchi K., Weskamp G., Lum L., Hammes H.P., Cai H., Brodie T.A., et al. Potential role for ADAM15 in pathological neovascularization in mice. Mol. Cell. Biol. 2003 Aug, 23(16):5614-5624.
139. Bohm B.B., Aigner T., Roy B., Brodie T.A., Blobel C.P., Burkhardt H. Homeostatic effects of the metalloproteinase disintegrin ADAM15 in degenerative cartilage remodeling. Arthritis Rheum. 2005 Apr, 52(4):1100-1109.
140. Maretzky T., Blobel C.P., Guaiquil V. Characterization of oxygen-induced retinopathy in mice carrying an inactivating point mutation in the catalytic site of ADAM15. Invest. Ophthalmol. Vis. Sci. 2014 Oct, 55(10):6774-6782.
141. Xie B., Shen J., Dong A., Swaim M., Hackett S.F., Wyder L., et al. An Adam15 amplification loop promotes vascular endothelial growth factor-induced ocular neovascularization. FASEB J. 2008 Aug, 22(8):2775-2783.
142. Sun C., Beard R.S., McLean D.L., Rigor R.R., Konia T., Wu M.H., et al. ADAM15 deficiency attenuates pulmonary hyperpermeability and acute lung injury in lipopolysaccharide-treated mice. Am. J. Physiol. Lung Cell Mol. Physiol. 2013 Feb 1, 304(3):L135-L142.
143. Marino M.W., Dunn A., Grail D., Inglese M., Noguchi Y., Richards E., et al. Characterization of tumor necrosis factor-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 1997 Jul 22, 94(15):8093-8098.
144. Kurisaki T., Masuda A., Osumi N., Nabeshima Y., Fujisawa-Sehara A. Spatially- and temporally-restricted expression of meltrin alpha (ADAM12) and beta (ADAM19) in mouse embryo. Mech. Dev. 1998 May, 73(2):211-215.
145. Nuttall R.K., Sampieri C.L., Pennington C.J., Gill S.E., Schultz G.A., Edwards D.R. Expression analysis of the entire MMP and TIMP gene families during mouse tissue development. FEBS Lett. 2004 Apr 9, 563(1-3):129-134.
146. Kurohara K., Komatsu K., Kurisaki T., Masuda A., Irie N., Asano M., et al. Essential roles of Meltrin beta (ADAM19) in heart development. Dev. Biol. 2004 Mar 1, 267(1):14-28.
147. Komatsu K., Wakatsuki S., Yamada S., Yamamura K., Miyazaki J., Sehara-Fujisawa A. Meltrin beta expressed in cardiac neural crest cells is required for ventricular septum formation of the heart. Dev. Biol. 2007 Mar 1, 303(1):82-92.
148. Lockhart M., Wirrig E., Phelps A., Wessels A. Extracellular matrix and heart development. Birth Defects Res. A Clin. Mol. Teratol. 2011 Jun, 91(6):535-550.
149. Kern C.B., Twal W.O., Mjaatvedt C.H., Fairey S.E., Toole B.P., Iruela-Arispe M.L., et al. Proteolytic cleavage of versican during cardiac cushion morphogenesis. Developmental Dynamics: An Official Publication of the American Association of Anatomists 2006 Aug, 235(8):2238-2247.
150. Stankunas K., Hang C.T., Tsun Z.Y., Chen H., Lee N.V., Wu J.I., et al. Endocardial Brg1 represses ADAMTS1 to maintain the microenvironment for myocardial morphogenesis. Dev. Cell 2008 Feb, 14(2):298-311.
151. McCulloch D.R., Nelson C.M., Dixon L.J., Silver D.L., Wylie J.D., Lindner V., et al. ADAMTS metalloproteases generate active versican fragments that regulate interdigital web regression. Dev. Cell 2009 Nov, 17(5):687-698.
152. Dupuis L.E., McCulloch D.R., McGarity J.D., Bahan A., Wessels A., Weber D., et al. Altered versican cleavage in ADAMTS5 deficient mice; a novel etiology of myxomatous valve disease. Dev. Biol. 2011 Sep 1, 357(1):152-164.
153. Kern C.B., Wessels A., McGarity J., Dixon L.J., Alston E., Argraves W.S., et al. Reduced versican cleavage due to Adamts9 haploinsufficiency is associated with cardiac and aortic anomalies. Matrix Biology: Journal of the International Society for Matrix Biology 2010 May, 29(4):304-316.
154. Jungers K.A., Le Goff C., Somerville R.P., Apte S.S. Adamts9 is widely expressed during mouse embryo development. Gene Expr. Patterns 2005 Jun, 5(5):609-617.
155. Koo B.H., Coe D.M., Dixon L.J., Somerville R.P., Nelson C.M., Wang L.W., et al. ADAMTS9 is a cell-autonomously acting, anti-angiogenic metalloprotease expressed by microvascular endothelial cells. Am. J. Pathol. 2010 Mar, 176(3):1494-1504.
156. Pickens B., Mao Y., Li D., Siegel D.L., Poncz M., Cines D.B., et al. Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models. Blood 2015 May 21, 125(21):3326-3334.
157. Sun Y., Huang J., Yang Z. The roles of ADAMTS in angiogenesis and cancer. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 2015 Apr, 28.
158. Rodriguez-Manzaneque J.C., Fernandez-Rodriguez R., Rodriguez-Baena F.J., Iruela-Arispe M.L. ADAMTS proteases in vascular biology. Matrix Biol. 2015, 44-46C:38-45.
159. Levula M., Airla N., Oksala N., Hernesniemi J.A., Pelto-Huikko M., Salenius J.P., et al. ADAM8 and its single nucleotide polymorphism 2662 T/G are associated with advanced atherosclerosis and fatal myocardial infarction: Tampere vascular study. Ann. Med. 2009, 41(7):497-507.
160. Raitoharju E., Seppala I., Levula M., Kuukasjarvi P., Laurikka J., Nikus K., et al. Common variation in the ADAM8 gene affects serum sADAM8 concentrations and the risk of myocardial infarction in two independent cohorts. Atherosclerosis 2011, 218(1):127-133.
161. Kim M., Suh J., Romano D., Truong M.H., Mullin K., Hooli B., et al. Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate [alpha]-secretase activity. Hum. Mol. Genet. 2009, 18(20):3987-3996.
162. Morange P.E., Tregouet D.A., Godefroy T., Saut N., Bickel C., Rupprecht H.J., et al. Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha converting enzyme (TACE/ADAM17) genes in relation to cardiovascular mortality: the AtheroGene study. J. Mol. Med. (Berl.) 2008, 86(10):1153-1161.
163. Junyent M., Parnell L.D., Lai C.Q., Arnett D.K., Tsai M.Y., Kabagambe E.K., et al. ADAM17_i33708A>G polymorphism interacts with dietary n-6 polyunsaturated fatty acids to modulate obesity risk in the Genetics of Lipid Lowering Drugs and Diet Network study. Nutr. Metab. Cardiovasc. Dis. 2010, 20(10):698-705.
164. Li Y., Yang C., Ma G., Cui L., Gu X., Chen Y., et al. Analysis of ADAM17 polymorphisms and susceptibility to sporadic abdominal aortic aneurysm. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology 2014, 33(5):1426-1438.
165. Sabatine M.S., Ploughman L., Simonsen K.L., Iakoubova O.A., Kirchgessner T.G., Ranade K., et al. Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy. Arterioscler. Thromb. Vasc. Biol. 2008, 28(3):562-567.
166. Li C., Xiong Y., Zhong Z., Zhang S., Peng Y., Wang L., et al. Association between a variant in ADAMTS5 and the susceptibility to hepatocellular carcinoma in a Chinese Han population. Cell Biochem. Biophys. 2014, 18.
167. Rodriguez-Lopez J., Mustafa Z., Pombo-Suarez M., Malizos K.N., Rego I., Blanco F.J., et al. Genetic variation including nonsynonymous polymorphisms of a major aggrecanase, ADAMTS-5, in susceptibility to osteoarthritis. Arthritis Rheum. 2008, 58(2):435-441.
168. Pu X., Xiao Q., Kiechl S., Chan K., Ng F.L., Gor S., et al. ADAMTS7 cleavage and vascular smooth muscle cell migration is affected by a coronary-artery-disease-associated variant. Am. J. Hum. Genet. 2013, 92(3):366-374.
169. Tseng S.C., Kimchi-Sarfaty C. SNPs in ADAMTS13. Pharmacogenomics 2011, 12(8):1147-1160.
170. Kokame K., Matsumoto M., Soejima K., Yagi H., Ishizashi H., Funato M., et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(18):11902-11907.
171. de Groot R., Lane D.A., Crawley J.T. The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity. Blood 2010, 116(16):3064-3072.
172. Kessler T., Zhang L., Liu Z., Yin X., Huang Y., Wang Y., et al. ADAMTS-7 inhibits re-endothelialization of injured arteries and promotes vascular remodeling through cleavage of thrombospondin-1. Circulation 2015, 131(13):1191-1201.
173. Maino A., Siegerink B., Lotta L.A., Crawley J.T., le Cessie S., Leebeek F.W., et al. Plasma ADAMTS-13 levels and the risk of myocardial infarction: an individual patient data meta-analysis. J. Thromb. Haemost. 2015, 13(8):1396-1404.
174. Soares R.P.S., Bydlowski S.P., Jatene M.B., Hironaka J.F., Lopes A.A. Decreased plasma ADAMTS-13 activity as a predictor of postoperative bleeding in cyanotic congenital heart disease. Clinics 2013, 68(4):531-536.
175. Wang X., Oka T., Chow F.L., Cooper S.B., Odenbach J., Lopaschuk G.D., et al. Tumor necrosis factor-[alpha]-converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis. Hypertension 2009, 6.
176. Zeng S.Y., Chen X., Chen S.R., Li Q., Wang Y.H., Zou J., et al. Upregulation of Nox4 promotes angiotensin II-induced epidermal growth factor receptor activation and subsequent cardiac hypertrophy by increasing ADAM17 expression. Can. J. Cardiol. 2013, 29(10):1310-1319.
177. Doggen K., Ray L., Mathieu M., Mc Entee K., Lemmens K., De Keulenaer G.W. Ventricular ErbB2/ErbB4 activation and downstream signaling in pacing-induced heart failure. J. Mol. Cell. Cardiol. 2009, 46(1):33-38.
178. Fan D., Takawale A., Shen M., Wang W., Wang X., Basu R., et al. Cardiomyocyte ADAM17 is essential in post-myocardial infarction repair by regulating angiogenesis. Circ. Heart. Fail. 2015, 1.
179. Weskamp G., Mendelson K., Swendeman S., Le Gall S., Ma Y., Lyman S., et al. Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes. Circ. Res. 2010, 106(5):932-940.
180. Swendeman S., Mendelson K., Weskamp G., Horiuchi K., Deutsch U., Scherle P., et al. VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling. Circ. Res. 2008, 103(9):916-918.
181. Zhou H.M., Weskamp G., Chesneau V., Sahin U., Vortkamp A., Horiuchi K., et al. Essential role for ADAM19 in cardiovascular morphogenesis. Mol. Cell. Biol. 2004, 24(1):96-104.
182. Thai S.N., Iruela-Arispe M.L. Expression of ADAMTS1 during murine development. Mech. Dev. 2002, 115(1-2):181-185.
183. Nakamura K., Hirohata S., Murakami T., Miyoshi T., Demircan K., Oohashi T., et al. Dynamic induction of ADAMTS1 gene in the early phase of acute myocardial infarction. J. Biochem. 2004, 136(4):439-446.
184. Bauer R.C., Tohyama J., Cui J., Cheng L., Yang J., Zhang X., et al. Knockout of Adamts7, a novel coronary artery disease locus in humans, reduces atherosclerosis in mice. Circulation 2015, 131(13):1202-1213.
185. Enomoto H., Nelson C.M., Somerville R.P., Mielke K., Dixon L.J., Powell K., et al. Cooperation of two ADAMTS metalloproteases in closure of the mouse palate identifies a requirement for versican proteolysis in regulating palatal mesenchyme proliferation. Development 2010, 137(23):4029-4038.
186. Banno F., Kokame K., Okuda T., Honda S., Miyata S., Kato H., et al. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood 2006, 107(8):3161-3166.